TheraCell announced that as of September 2020, its royalty income from licensees of its base demineralized bone fiber technology has surpassed a $1 million annual run rate. With consistent quarter over quarter growth, this achievement represents a 55% increase over the annual run rate observed at the same time last year.
TheraCell has licensed the technology to AlloSource to produce and market AlloFuse® Cortical Fibers and AlloFuse Fiber Boats, and to produce private-label products to be marketed by other orthopedic companies. The technology has also been licensed to Australian Biotechnologies to produce AlloVance® Xpress Fibres, AlloVance Xpress Hybrid, AlloVance Fibre Mats and AlloVance Fibre Boats for Australia and New Zealand.
TheraCell has also launched a comprehensive portfolio of TheraFuze DBF® graft solutions.
"This is a significant milestone for TheraCell," said Bradley Patt, Ph.D., TheraCell's President and CEO. "We are very pleased with the success our licensees are having in the market with the original cortical fiber products. We believe that this is an exciting base off of which to launch our full portfolio of unique TheraFuze DBF® graft forms."